JOURNAL CONTENT
CONTACT

Submission of the manuscript is online via e-mail
ecgarticle@gmail.com or
cholerez@mail.ru

Tel: +7 903 250 5288

Editorial Correspondence e-mail
gastrossr@gmail.com


Publishing, Subscriptions, Sales and Advertising, Correspondence e-mail
journal@cniig.ru

Tel: +7 917 561 9505

THE RULES OF SUBMITTING AN ARTICLE

READ

Scimago Journal & Country Rank

SCImago Journal & Country Rank

LEADING ARTICLE

    1. Scientific and clinical center of gastroenterology and Hepatology, Saint Petersburg state University (St. Petersburg, Russian Federation)

    Keywords:NSAIDs colonopathy,NSAIDs colonopathy risk factors,NSAIDs colonopathy early diagnosis,prevention and treatment

    Abstract:Purpose: to study the incidence of NSAIDs-induced colonopathy in inpatient and outpatient medical institutions in Saint-Petersburg, to analyze their clinical manifestations, special features of their prevention and treatment. Materials and methods. In 112 patients within the age limit of 44-83 years characteristics of occurrence and symptoms of NSAIDs-induced colonopathy were studied in 12 Saint-Petersburg inpatient and outpatient medical institutions. Most of the patients were observed by rheumatologists, orthopedists, neurologists and cardiologists. 77.6 % were given non-selective NSAIDs, the rest - selective. Besides standardized blood analysis the patients underwent fibrogastroduodenoscopy, fibrocolonoscopy, jejunoscopy, in 3 cases - total capsule endoscopy, in 67 cases mucosa biopsy followed by its histologic analysis Results and Discussion. NSAID colonopathy occurred in 12 % of 933 patients. Their gastrointestinal lesions were associated with NSAIDs. 51.7 % patients with NSAIDs colonopathy had different gastrointestinal disorders - nausea, vomiting, heartburn, constipation, pains in the epigastrium or mesogastrium, acute and chronic diarrhea. Intestinal bleeding was in 7.2 % of patients, in 4 of them there were no prodromal subjective manifestations and bleeding occurred spontaneously. Intestinal perforation was in 2.7 % of patients with NSAIDs colonopathy. Basing on literary data and own experience 7 risk factors of NSAIDs colonopathy were formed. The most important were advanced age, organic intestinal pathology in the anamnesis and simultaneous intake of NSAIDs and glucocorticoids. Data showing inadequate consideration of risk factors by clinicians and algorithms of prevention and early diagnosis of NSAIDs colonopathy are presented, which significantly influence the incidence of this pathology. Data concerning modern ideas of dietary and pharmacological approaches to NSAIDs colonopathy prevention and treatment are described.

      1. Morrissey M. B., Herr K., Levine C. Public health imperative of the 21st century: innovations in palliative care systems, services, and supports to improve health and well-being of older Americans// Gerontologist, 2015. - Vol. 55(2), p. 245-51.
      2. Каратеев А. Е., Насонов Е. Л., Яхно Н. Н. и др. Клинические рекомендации «Рациональное применение нестероидных про-тивовоспалительных препаратов (НПВП) в клинической практике»// Современная ревматология, 2015. - № 9(1), с. 4-24.
      3. Brune K., Patrignani P. New insights into the use of currently available non-steroidal anti-inflammatory drugs// J. Pain. Res., 2015. - Vol. 20, № 8. - р. 105-118.
      4. Murray C. J., Barber R. M., Foreman K. J., et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quan-tifying the epidemiological transition// Lancet, 2015. - Vol. 28, p. 2145-2191.
      5. Wilson N., Sanchez-Riera L., Morros R., et al. Drug utilization in patients with OA: a population-based study// Rheumatology (Oxford), 2015, May. - Vol. 54(5), р. 860-867.
      6. Breivik H., Collett B., Ventafridda V., et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment// Eur. J. Pain, 2006. - May; Vol. 10(4), р. 287-333.
      7. Насонов Е. Л., Каратеев А. Е. Нестероидные противовоспалительные препараты: клинические рекомендации по использованию//Врач, 2007. - № 3, с. 37-42.
      8. Harirforoosh S., Asghar W., Jamali F. Adverse effects of nonsteroidal antiinflamma-tory drugs: an update of gastrointestinal, car-diovascular and renal complications// J. Pharm. Pharm. Sci., 2013. - Vol. 16 (5), р. 821-847.
      9. Maiden L., Thjodleifsson B., Seigal A., et al. Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional capsule enteroscopy study// Clin. Gastroenterol. Hepatol., 2007. - Vol. 5(9), р. 1040-1045.
      10. Lichtenberger L. M., Zhou Y., Dial E. J., Raphael R. M. NSAID injury to the gastrointestinal tract: evidence that NSAIDs interact with phospholipids to weaken the hydrophobic surface barrier and induce the formation of unstable pores in membranes// J. Pharm. Pharmacol., 2006. - Vol. 58 (11), р. 1421-1428.
      11. Lim Yu. J., Lee J. S., Ku Ya. S., Hahm K. - B. Rescue strategies against non-steroidal anti-inflammatory drug-induced gastroduodenal damage. // J. Gastroenterol. Hepatol., 2009. - Vol. 24, р. 1169-1178.
      12. Максимов М. Л. Актуальные вопросы эффективности и безопасности современных нестероидных противовоспалительных препаратов. РМЖ. 2014. № 28. С. 2015 Максимов М. Л. Актуальные вопросы эффективности и безопасности современных нестероидных противовоспалительных препаратов. РМЖ. 2014. № 28. С. 2015
      13. Bjarnason I., Zanelli G., Prouse P. et al. Effect of non-steroidal anti-inflammatory drugson the human small intestine// Drugs, 1986 Vol. 32 (Suppl), р. 35-41.
      14. Allison M. C., Howatson A. G., Torrance C. J. et al. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs// N. Engl. J. Med., 1992. - Vol. 327, р. 751-756.
      15. Chan F. K.L., Lanas A., Scheiman J. et al. Celecoxib versus omeprazole and diclofenac in patients with ostheoarthritis and rheumatoid arthritis (CONDOR): a randomised trial// The Lancet, 2010. - Vol. 376 (9736), р. 173-179.
      16. Scheiman J. M., Fendrick A. M. Summing the risk of NSAID therapy// The Lancet, 2007. - Vol. 369, р. 1580-1581.
      17. Langman M. J.S., Morgan L., Worall A. Use of inflammatory drugs by patients admitted with small or large bowel perforations and hemorrhage// Br. Med. J., 1985. - Vol. 290, р. 347-349.
      18. Smale S., Tibble J., Sigthorsson G., Bjarnason I. Epidemiology and differential diagnosis of NSAID-induced injury to the mucosa of the small intestine// Best Pract. Res. Clin. Gastroenterol., 2001. - Vol. 15, р. 723-738.
      19. Damms A., Bischoff S. C. Validation and clinical significance of a new calprotectin rapid test for the diagnosis of gastrointestinal diseases// Int. J. Colorectal Dis., 2008. - Vol. 23, р. 985-992.
      20. Syer S. D D., Wallace J. L. Environmental and NSAID-Enteropathy: Dysbiosis as a Common Factor// Curr. Gastroenterol. Rep., 2014. - Vol. 16, р. 377-342.
      21. Andreasson K., Scheja A., Saxne T., Ohlsson B., Hesselstrand R. Faecal calprotectin: a biomarker of gastrointestinal disease in systemic sclerosis// J. Intern. Med., 2011. - Vol. 270, р. 50-57.
      22. Lee I. S., Cho Y. K. Initial Steps to Prevent Nonsteroidal Anti-Inflammatory Drug- or AspirinInduced Enteropathy: Long-Term Outcome Data// Gut and Liver, November 2015. - Vol. 9, No. 6. - Р. 697-698.
      23. Hawkey C. J., Lanas A. I. Doubt and certainty about nonsteroidal anti-inflammatory drugs in the year 2000: a multidisciplinary expert statement. // Am. J. Med. - 2001. - V. 110. - P. 79S-100S.
      24. Балабанцева А. П., Кляритская И. Л., Цапяк Т. А., Григоренко Е. И. Современные подходы к первичной профилактике НПВП-индуцированных гастропатий и энтеропатий// Крымский терапевтический журнал, 2015. - № 3, с. 31-37.
      25. Бадокин В. В. Сложности выбора оптимального нестероидного противовоспалительного препарата: в фокусе мелоксикам// РМЖ, 2016 № 6. - С. 1772-1776.
      26. Липатова Т. Е., Дудаева Н. Г. Современная стратегия диагностики и лечения НПВП-индуцированной энтеропатии у пожилых пациентов. Саратовский научно-медицинский журнал 2015; 11 (1): 52-56.
      27. Мороз Е. В., Каратеев А. Е. Ребамипид: эффективная медикаментозная профилактика НПВП-энтеропатии возможна//Современная ревматология, 2016, № 4. - С. 97-105.
      28. Are C., Turagam M., Aucar J. A., Greenberg E. Meloxicam-induced enteropathy of the small bowel//Canadian Medical Association Journal, March 22, 2011. - 183(5), р. 577-580.
      29. Wallace J. L. Prevention of NSAID-Enteropathy: A Soluble Problem?// Dig. Dis. Sci., 2016. Vol. 61, p. 1-3.
      30. Ishihara M., Ohmiya N., Nakamura M., Funasaka K. at al. Risk factors of symptomatic NSAID-induced small intestinal injury and diaphragm disease//Alimentary Pharmacology and Therapeutics, 2014, Vol. 40. - P. 538-547.
      31. Watanabe T., Nishio H., Tanigawa T. et al. Probiotic Lactobacillus casei strain Shirota prevents indomethacin-induced small intestinal injury: involvement of lactic acid// Am. J. Physiol. Gastrointest.
      32. Liver Physiol., 2009. - Vol. 297, G506-G513.
      33. Syer S. D., Blackler R. W., Martin R. et al. NSAID enteropathy and acteria: a complicated relationship. J. Gastroenterol., 2015. Vol. 50, p. 387-393.
      34. Akiba Y., Inoue T., Kaji I. et al. Short-chain fatty acid sensing in rat duodenum//J. Physiol., 2015,. - Vol. 593, р. 585-599.
      35. Inoue T., Higashiyama M., Kaji I. et al. Dipeptidyl peptidase IV inhibition prevents the formation and promotes the healing of indomethacin-induced intestinal ulcers in rats// Dig. Dis. Sci., 2014, Vol. 59, р. 1286-1295.
      36. Licht T. R., Hansen M., Bergstrom A. et al. Effects of apples and specific apple components on the cecal environment of сonventional rats: role of apple pectin// BMC Microbiol., 2010. - № 10, р. 13.
      37. Диетология. 5-е изд./Под ред. А. Ю. Барановского. - СПБ.: Питер, 2017. - 1104 с.
      38. Montalto M., Gallo A., Gasbarrini A., Landolf R. NSAID enteropathy: could probiotics prevent it?//J. Gastroenterol., 2013. - Vol. 48, р. 689-697.
      39. Барановский А. Ю., Балтрукова Т. Б., Голощапов О. Д. Экологическая диетология. Часть I. Диетическая радиопротекция. 2-е издание, 2014. - 232 с.
      40. Blackler R. W., Gemici B., Manko A., Wallace J. L. NSAID-gastroenteropathy: new aspects of pathogenesis and prevention//Current Opinion in Pharmacology, 2014, № 19. - р. 11-16.
      41. Marlicz W., Łoniewsk I., Grimes D., Quigley E. M. Nonsteroidal Anti-inflammatory Drugs, Proton Pump Inhibitors, and Gastrointestinal Injury: Contrasting Interactions in the Stomach and Small Intestine// Mayo Clin. Proc., December 2014, № 89 (12). - р. 1699-1709.
      42. Somerville K. W., Hawkey C. J. Non-steroidal anti-inflammatory agents and the gastrointestinal tract// Postgraduate Medical Journal, 1986. - № 62, р. 23-28.
      43. Lanza F. L., Chan F. K., Quigley E. M. Guidelines for prevention of NSAID-related ulcer complications //Am. J. Gastroenterol., 2009. - Vol. 104, p. 728-738.
      44. Lim Y. J., Lee J. S., Ku Y. S., Hahm K. B. Rescue strategies against non-steroidal anti-inflammatory drug-induced gastroduodenal damage. //J. Gastroenterol. Hepatol., 2009. - № 24, p. 1169-1178.
      45. Bjarnason I., Takeuchi K. Intestinal permeability in the pathogenesis of NSAID-induced enteropathy //J. Gastroenterol.,2009. - Vol. 44. - Suppl 19. - p. 23-29.
      46. Fujimori S., Takahashi Y., Seo T. et al. Prevention of traditional NSAIDinduced small intestinal injury: recent preliminary studies using capsule endoscopy //Digestion, 2010. - Vol. 82, p. 167-172.
      47. Fortun P. J., Hawkey C. J. Nonsteroidal antiinflammatory drugs and the intestine. //Curr. Opin. Gastroenterol., 2007. - № 23, p. 134-141.
      48. Wallace J. L., Ferraz J. G. New pharmacological therapies in gastrointestinal disease.//Gastroenterol. Clin. North. Am., 2010. - Vol. 39, p. 709-720.
      49. Adebayo D., Bjarnason I. Is non-steroidal anti-inflammaory drug (NSAID) enteropathy clinically more important than NSAID gastropathy? //Postgrad. Med. J., 2006. - Vol. 82. - p. 186-191.
      50. Ткач С. М., А. П. Балабанцева А. П. Современные подходы к лечению НПВП-энтеропатий// Сучасна гастроентерологія, 2014. - № 6 (80), с. 142-148.
      51. Каратеев А. Е. Что лучше для профилактики НПВП-гастропатии: коксибы или комбинация «традиционных» НПВП и гастропротектора?// РМЖ, 2013. - № 13, с. 673-680.
      52. Niwa Y., Nakamura M., Ohmiya N. et al. Efficacy of rebamipide for diclofenac-induced small-intestinal mucosal injuries in healthy subjects: a prospective, randomized, double-blinded, placebo-controlled, cross-over study //J. Gastroenterol., 2008. -Vol. 43. - p. 270-276.
      53. Thiéfin G., Beaugerie L. Toxic effects of nonsteroidal antiinflammatory drugs on the small bowel, colon, and rectum. //Joint. Bone Spine., 2005. - Vol. 72, p. 286-294.
      54. Hagiwara M., Kataoka K., Arimochi H. et al. Inhibitory effect of fluvastatin on ileal ulcer formation in rats induced by nonsteroidal antiinflammatory drug //World J. Gastroenterol., 2005. - № 11, р. 1040-1043.
      55. Kato S., Nishio H., Ogura M., Takeuchi K. Tacrolimus (FK506), an immunosuppressive agent, prevents indomethacin-induced small intestinal ulceration in the rat: inhibition of inducible nitric oxide synthase expression // J. Pharmacol. Sci., 2007. - Vol. 103, p. 40-47.
     


    Full text is published :
    Baranovsky A.Yu. DIAGNOSTICS, PREVENTION AND TREATMENT OF NSAIDS-INDUCED COLONOPATHY. Experimental and Clinical Gastroenterology Journal. 2017;146(10):04-14
    Read & Download full text